SCHEMBL15901671

SCHEMBL15901671

COC(=O)CCc1ccc2[nH]ccc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 4/20 0.54
HDAC8 Q9BY41 2/20 0.54
ABL1 P00519 1/20 0.46
SRC P12931 1/20 0.46
BACE1 P56817 2/20 0.45
PDE3B Q13370 1/20 0.44
PDE3A Q14432 1/20 0.44
P2RY12 Q9H244 1/20 0.44
CTNNB1 P35222 2/20 0.44
WNT3A P56704 2/20 0.44
ENPP2 Q13822 1/20 0.44
MAOA P21397 2/20 0.44
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
TUBB4A P04350 1/20 0.43
TUBB P07437 1/20 0.43
TUBA3C P0DPH7 1/20 0.43
TUBA1B P68363 1/20 0.43
TUBA4A P68366 1/20 0.43
TUBB4B P68371 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11976581 0.88 ABL1 (0.46) HDAC1HDAC8ABL1BACE1PDE3B
SCHEMBL3687535 0.85 ENPP2 (0.44) HDAC1HDAC8BACE1ENPP2MAOB
SCHEMBL16180236 0.85 HDAC1 (0.53) HDAC1HDAC8ABL1SRCBACE1
SCHEMBL4883079 0.83 HDAC1 (0.55) HDAC1HDAC8CTNNB1WNT3AENPP2
SCHEMBL6263512 0.81 HDAC1 (0.56) HDAC1HDAC8CTNNB1WNT3A
SCHEMBL21617914 0.81 LMNA (0.60) MAOAKDM4ENPC1LMNATP53
SCHEMBL6844115 0.80 HDAC1 (0.55) HDAC1HDAC8CTNNB1WNT3AENPP2
SCHEMBL3882301 0.80 HDAC1 (0.41) HDAC1HDAC8PDE3BPDE3AP2RY12
SCHEMBL1732676 0.80 ABL1 (0.49) HDAC1HDAC8ABL1SRCBACE1
SCHEMBL6303056 0.79 HDAC1 (0.51) HDAC1HDAC8ABL1SRCCTNNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12012411-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-18 US disclosed
US-20220106321-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-04-07 US disclosed
US-11279704-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-03-22 US disclosed
CN-108440370-B Inhibitors of viral replication 鲁汶天主教大学 2021-07-30 CN disclosed
EP-3617192-A1 VIRAL REPLICATION INHIBITORS Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2020-03-04 EP disclosed
US-10550123-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2020-02-04 US disclosed
US-20190337954-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2019-11-07 US disclosed
EP-2760831-B1 VIRAL REPLICATION INHIBITORS UNIV LEUVEN KATH (BE) 2019-08-07 EP disclosed
CN-104024223-A Inhibitors of viral replication UNIV LEUVEN KATH 2014-09-03 CN disclosed
US-20140213586-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213586-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 HDAC1 1390/4885HDAC8 1975/4885ABL1 304/4885
US-11279704-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 HDAC1 1390/4885HDAC8 1975/4885ABL1 304/4885
US-20190337954-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 HDAC1 1390/4885HDAC8 1975/4885ABL1 304/4885
US-10550123-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 HDAC1 1390/4885HDAC8 1975/4885ABL1 304/4885
US-20220106321-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 HDAC1 1390/4885HDAC8 1975/4885ABL1 304/4885
US-12012411-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 HDAC1 1390/4885HDAC8 1975/4885ABL1 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.